Presentation is loading. Please wait.

Presentation is loading. Please wait.

Kastelein JJ, et al. Circulation 2008;117:3002-9 On-Treatment Values of Lipids, Apolipoproteins, and Their Ratios in Both Treatment Groups of TNT and IDEAL.

Published byAngelica Edwards Modified over 9 years ago

Similar presentations

Presentation on theme: "Kastelein JJ, et al. Circulation 2008;117:3002-9 On-Treatment Values of Lipids, Apolipoproteins, and Their Ratios in Both Treatment Groups of TNT and IDEAL."— Presentation transcript:

1 Kastelein JJ, et al. Circulation 2008;117:3002-9 On-Treatment Values of Lipids, Apolipoproteins, and Their Ratios in Both Treatment Groups of TNT and IDEAL

2 Individual Relationships Between On-Treatment Levels of LDL Cholesterol, Non-HDL Cholesterol, Apolipoprotein B, or Their Ratios and MCVEs in TNT and IDEAL Kastelein JJ, et al. Circulation 2008;117:3002-9

3 Direct Pairwise Comparisons of the Relationships With MCVEs for On-Treatment Levels of LDL Cholesterol, Non-HDL Cholesterol, Apolipoprotein B, or Their Ratios in TNT and IDEAL Kastelein JJ, et al. Circulation 2008;117:3002-9 *Calculated by a Cox proportional hazard model with adjustment for the effects of study, age, and sex. †Calculated as total cholesterol minus HDL cholesterol.

4 Individual Relationships Between On-Treatment Levels of LDL Cholesterol, Non-HDL Cholesterol, Apolipoprotein B, or Their Ratios and MCVEs in Selected Subgroups of TNT and IDEAL Kastelein JJ, et al. Circulation 2008;117:3002-9 *Calculated by a Cox proportional hazard model with adjustment for the effects of study, age, and sex. †Calculated as total cholesterol minus HDL cholesterol.

5 Kastelein JJ, et al. Circulation 2008;117:3002-9 CLINICAL PERSPECTIVE

Download ppt "Kastelein JJ, et al. Circulation 2008;117:3002-9 On-Treatment Values of Lipids, Apolipoproteins, and Their Ratios in Both Treatment Groups of TNT and IDEAL."

Similar presentations

Meredith Cook Mercer COPHS August,2012. Total Cholesterol HDL Could CVD prediction be improved by also assessing additional lipid-related markers (replacing.

Meredith Cook Mercer COPHS August,2012. Total Cholesterol HDL Could CVD prediction be improved by also assessing additional lipid-related markers (replacing.
Relationship of LDL-C & LDL-P. Lipoprotein Particles LipoScience 2007 NON-POLAR LIPID CORE Cholesterol Ester Triglyceride POLAR SURFACE COAT Phospholipid.

Relationship of LDL-C & LDL-P. Lipoprotein Particles LipoScience 2007 NON-POLAR LIPID CORE Cholesterol Ester Triglyceride POLAR SURFACE COAT Phospholipid.
Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]
Break the Fast: “Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control.

Break the Fast: “Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control.
Lipid Disorders and Management in Diabetes

Lipid Disorders and Management in Diabetes
Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-

Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-
Blood samples available from study participants with myocardial infarction and controls by ethnic origin Matthew J McQueen, et al. Lancet 2008; 372: 224-33.

Blood samples available from study participants with myocardial infarction and controls by ethnic origin Matthew J McQueen, et al. Lancet 2008; 372:
Slide Source: www.lipidsonline.org Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.

Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.
* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.
Women and Cholesterol What You Need to Know. Age: 45 Women and Cholesterol: What You Need to Know HDL: 60 mg/dL and above LDL: Below 100 mg/dL GoodBad.

Women and Cholesterol What You Need to Know. Age: 45 Women and Cholesterol: What You Need to Know HDL: 60 mg/dL and above LDL: Below 100 mg/dL GoodBad.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol 5.5-8.0 Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
Philip J. Barter, et al. Circulation 2011;124:555-562.

Philip J. Barter, et al. Circulation 2011;124:
PPAR  activation & lipid metabolism. Diabetic dyslipidaemia Lipid profiles and hyperinsulinaemia in newly diagnosed type 2 diabetic patients Niskanen.

PPAR  activation & lipid metabolism. Diabetic dyslipidaemia Lipid profiles and hyperinsulinaemia in newly diagnosed type 2 diabetic patients Niskanen.
Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:1556-1563.

Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:
Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:2560-72.

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:
Parish S, et al. Eur Heart J 2009 [Epub ahead of print]

Parish S, et al. Eur Heart J 2009 [Epub ahead of print]
Ridker PM, et al. Lancet 2009;373:1175-82. Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.
Trial profile Prakash Deedwania, et al. Lancet 2006; 368: 919-28.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Lipid Profile, Plasma Apolipoproteins, and Risk of.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Lipid Profile, Plasma Apolipoproteins, and Risk of.
Date of download: 6/25/2016 Copyright © 2016 American Medical Association. All rights reserved. From: The Colorado Thyroid Disease Prevalence Study Arch.

Date of download: 6/25/2016 Copyright © 2016 American Medical Association. All rights reserved. From: The Colorado Thyroid Disease Prevalence Study Arch.

Similar presentations

Ads by Google